Startup Applied Molecular Transport is aiming to mimic the systems used by naturally occurring microbes in the gastrointestinal tract to develop oral biologics that can cross the organ's barriers. Johnson & Johnson demonstrated its interest in the drug delivery paradigm by making the company one of the 10 first occupants of its life science incubator in South San Francisco.
Japan's Eisai sold the worldwide rights, excluding Japan, to Phase I/II cancer candidate EP-6438 to U.S.-based Epizyme for $40 million upfront, revising a 2011 agreement on discovery, development and commercialization of a therapy aimed at non-Hodgkin B-cell lymphoma and other cancers.
Validic, the provider of a digital health platform, is partnering with health information technology supplier Cerner. Using Validic's digital health platform, Cerner will integrate clinical, fitness, wellness and nutritional data into the HealtheLifeSM personal health portal.
The Bill & Melinda Gates Foundation announced this week it's betting on CureVac, a move both Sanofi and Boehringer Ingelheim made last year, committing to an mRNA technology designed to make vaccines less expensive and easier to make.
Chemistry and biology are joining hands in China in ways that will have a profound impact on biotechnology startups and more established companies, but it is still early days for many companies and more money from venture capitalists or other funding sources is welcome.
A month after Genmab and Johnson & Johnson's Janssen released successful mid-stage data for its multiple myeloma antibody daratumumab, Halozyme has jumped on board, planning a Phase I trial with its subcutaneous delivery technology.
Natco Pharma won another battle in its quest to knock down patent barriers to its generic drugs, this time for a version of the Gilead Sciences' influenza treatment, Tamiflu (oseltamivir).
Mindera, the developer of a microneedle-based molecular diagnostic system for skin cancer, was among the first 10 resident companies at Johnson & Johnson's just-opened JLABS life science incubator in San Francisco. That means that the life science bigwig believes Mindera's technology is novel and of interest to one of the many companies under its umbrella.
Dara BioSciences is the new marketer of the only orally dissolving buccal tablet approved for oral thrush, which occurs when the Candida albicans fungus grows in the lining of the mouth.
Cancer diagnostics has long been defined by the aim of providing "personalized" and "precision" medicine to patients. But now the buzzword of the moment seems to be trending more toward "universal"--as the industry strives for an all-encompassing test that will mete out the best possible individual treatment protocols based on genomic data.